Drug Type Natural Killer Cell Therapies |
Synonyms MYJ 1633, MYJ1633, MYJ1633-BCS + [3] |
Target- |
Mechanism- |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseNDA/BLA |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | NDA/BLA | KR | - | |
Gastrointestinal cancer metastatic | Phase 2 | KR | - | |
HER2 Positive Breast Cancer | Phase 2 | KR | - | |
Stomach Cancer | Phase 2 | KR | - | |
Triple Negative Breast Cancer | Preclinical | KR | 05 Jun 2024 |